Dipal Doshi, Chief Executive Officer - Entrada Therapeutics (TRDA)
Dipal Doshi is a distinguished leader in the biotechnology sector, currently serving as the Director and Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), a clinical-stage biotechnology company dedicated to developing intracellular therapeutics to treat devastating diseases. “We value intellectual curiosity and enjoy the challenge of fighting the good fight—waking up each day to advance our science one step closer to helping patients and their caregivers who deserve better treatments,” says Doshi. He joined Entrada Therapeutics in 2017 as its first full-time employee, shortly after its founding and initial seed funding. Since then, he has served as CEO and a Member of the Board of Directors, with his tenure including the role of President and CEO from 2017 to 2023.
With over two decades of experience in the pharmaceutical industry, he has been instrumental in advancing innovative therapies that transform the treatment landscape for patients with severe diseases. His expertise spans drug development, corporate strategy, and business development, making him a pivotal figure.
Doshi has served as Chief Business Officer at Amicus Therapeutics, where he led the business and corporate development initiatives, global strategy, and product planning. This role provided him with valuable insights into the complexities of drug development and commercialization. He holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. He is a Fellow of the Aspen Institute, serves on the Board of Advisors of Life Science Cares Boston and is a member of the Board of Directors at āshibio, a privately held, clinical-stage biotechnology company.
Under Doshi’s leadership, Entrada Therapeutics has become a leader in intracellular therapeutics. One of his notable achievements was leading the firm through a successful $116 million Series B financing in March 2021, which advanced the company’s innovative pipeline. This funding was critical for developing therapies targeting rare genetic diseases, particularly through the company’s proprietary Endosomal Escape Vehicle (EEV™) technology.
The company has made significant progress in its clinical programs, including advancing oligonucleotide therapies for conditions such as Duchenne muscular dystrophy (DMD). Its lead candidate, ENTR-601-44, is currently in Phase 1 clinical trials. This program aims to address specific mutations in DMD patients amenable to exon skipping, showcasing Doshi’s commitment to addressing unmet medical needs.
Doshi has also fostered strategic partnerships to strengthen Entrada Therapeutics’ capabilities. Notably, he facilitated a collaboration with Vertex Pharmaceuticals to develop treatments for myotonic dystrophy type 1 (DM1), expanding the company’s therapeutic reach. In addition, he championed diversity and inclusion initiatives within the biotechnology sector, including the Entrada DREAMS Grant Program, which supports diversity efforts in the Duchenne community. This program highlights his commitment to addressing health disparities and ensuring innovative therapies reach underserved populations.
The company has made significant progress in its clinical programs, including advancing oligonucleotide therapies for conditions such as Duchenne muscular dystrophy (DMD). Its lead candidate, ENTR-601-44, is currently in Phase 1 clinical trials. This program aims to address specific mutations in DMD patients amenable to exon skipping, showcasing Doshi’s commitment to addressing unmet medical needs.
Doshi has also fostered strategic partnerships to strengthen Entrada Therapeutics’ capabilities. Notably, he facilitated a collaboration with Vertex Pharmaceuticals to develop treatments for myotonic dystrophy type 1 (DM1), expanding the company’s therapeutic reach. In addition, he championed diversity and inclusion initiatives within the biotechnology sector, including the Entrada DREAMS Grant Program, which supports diversity efforts in the Duchenne community. This program highlights his commitment to addressing health disparities and ensuring innovative therapies reach underserved populations.
"We value intellectual curiosity and enjoy the challenge of fighting the good fight—waking up each day to advance our science one step closer to helping patients and their caregivers who deserve better treatments. "
Looking ahead, Doshi aims to expand Entrada Therapeuctics’ focus beyond neuromuscular diseases, exploring new therapeutic areas in immunology and metabolic disorders. By leveraging advancements in drug delivery systems, he will unlock new treatment avenues for diseases that currently lack effective therapies. He emphasizes maintaining strong relationships with investors and stakeholders to secure ongoing funding for research and development initiatives.
With robust financial backing and a clear strategic direction, he is poised to lead Entrada Therapeutics into a future where its groundbreaking therapies can significantly improve patient outcomes. His achievements provide a solid foundation for future innovations that have the potential to redefine treatment paradigms across multiple disease areas.